FDA Rejects Nasal Spray For Severe Allergic Reactions—

ARS Pharmaceuticals chief executive Richard Lowenthal said the company is “very surprised” and “deeply disappointed” by the FDA’s decision.

Related Keywords

Oak Brook , Illinois , United States , Richard Lowenthal , Zachary Rubin , Drug Administration On , Drug Administration , Oak Brook Allergists , Fda , Food And Drug Administration , Epipen , Neffy , Ars Pharmaceuticals , Needle Free , Injector , Anaphylaxis , Epinephrine , Allergic Reaction ,